Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review.
about
Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodiesEpitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis.ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal diseaseAutomatic reading of ANCA-slides: evaluation of the AKLIDES system.Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful?EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Autoimmunity in kidney diseases.The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU).Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GNAn approach to the diagnosis and management of systemic vasculitis.Update on the use of biologics in primary systemic vasculitides.Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.Autoantibodies in the grocery shop: does quantity matter?Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Biomarkers in ANCA-associated vasculitis.Treatment of ANCA-associated vasculitis.Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.A case of phenotypic and serological transformation in Wegener's granulomatosis.EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.Sudden and rapid progression of lung affectation but stability in kidney function: a case report of anti-neutrophil cytoplasmic antibody-associated vasculitis.Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis.Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitisGalactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis.Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis.Diagnostic outcome and indications for testing in patients with positive ANCA at a Canadian tertiary care centre.Persistent Hematuria in ANCA Vasculitis: Ominous or Innocuous?ANCA-positive vasculitis: Clinical implications of ANCA types and titers.Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's)Role of the clinical immunology laboratory in disease monitoring
P2860
Q27000411-13BE784D-AD61-49EB-B5FF-D9CF29C4160DQ34663785-7FE20061-FD01-4CE8-996A-13D4899F5D7AQ35124231-56D318F8-D7DB-409B-B0EB-E2B9F9719F5DQ36410589-32FEC157-A7E7-4E91-8985-E398667410B5Q36560767-B792F13E-E33D-43D0-A1E7-3F3C594E4F16Q36684589-D4DF10B7-3067-46C9-8F54-3329AE932FBDQ37196899-8288E43A-3185-45A0-A38F-0ED8B637DE7CQ37467895-BBA62DA1-FC0C-480B-900D-E5144E5EAA08Q37604720-BDA2AC83-4291-4EA2-A512-6170C7CECABBQ37673239-BD7F63A8-A415-4026-BE42-AE1CC1C79B43Q37754811-8775A546-9932-49C8-A174-9CC1A31C718DQ38016064-6EE67418-8047-4115-934A-E623F5810D7FQ38097752-7CF93287-2ECF-4DE3-85F9-73EB2774B1FDQ38100780-1A5EFC51-9E28-4F0D-BDE1-7D34CD163F4BQ38129720-6163A481-9A24-4C21-9C5F-8DB118C32037Q38159916-ACD8CB5C-367A-4FB9-B935-1953E1AF46DAQ38204971-AEB432A4-FA46-4719-BC79-FF8FE560C488Q38840696-17D4C26B-CE7F-4DEE-BC27-49FA35973CE3Q39993490-DBD48C59-DC49-4750-BCE6-8ABC530016F0Q40334893-D2EE7667-453E-4E37-A661-172D855C5C27Q40684657-E87F8DC8-0AEA-4FC9-A2DF-0762D50B8932Q41856154-803B6BA2-7E58-4A8F-83FF-7B06509CEA30Q41892986-0E742968-EDAA-418D-AEEE-691F39213114Q41992856-99C9F978-8135-4CC3-A505-BA7351E109ACQ42069958-1AAA0F07-7EF3-447E-964D-FB14A461594CQ46081324-280A8D9B-805F-44DC-B532-33C2EF165C01Q48113738-93B56347-FB57-4A30-B5A6-BA4C21BA66B7Q49681692-06C05FFD-0A14-415B-A47B-BE04D3C60CC9Q51475555-22473406-461D-43BE-BB40-C89513FD08F1Q58004245-EE3002A5-EB7D-4DE9-ADF8-B0E2C1C90465Q59102177-9B81291F-DD0D-4A3F-948D-940BB7737A83
P2860
Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Serial ANCA determinations for ...... vasculitis: systematic review.
@ast
Serial ANCA determinations for ...... vasculitis: systematic review.
@en
type
label
Serial ANCA determinations for ...... vasculitis: systematic review.
@ast
Serial ANCA determinations for ...... vasculitis: systematic review.
@en
prefLabel
Serial ANCA determinations for ...... vasculitis: systematic review.
@ast
Serial ANCA determinations for ...... vasculitis: systematic review.
@en
P2093
P1476
Serial ANCA determinations for ...... vasculitis: systematic review.
@en
P2093
Fokko J van der Woude
Isabelle A Kaelsch
Rainer Birck
Wilhelm H Schmitt
P356
10.1053/J.AJKD.2005.09.022
P577
2006-01-01T00:00:00Z